Zobrazeno 1 - 10
of 4 170
pro vyhledávání: '"de Botton, S."'
Autor:
Guerra M; Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Villejuif, France., Alouani E; Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Villejuif, France., Hueso T; Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Villejuif, France., Ouali K; Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Villejuif, France., Danu A; Département d'Hématologie, Gustave Roussy, Villejuif, France., Hollebecque A; Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Villejuif, France., Bahleda R; Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Villejuif, France., Willekens C; Département d'Hématologie, Gustave Roussy, Villejuif, France., Gazzah A; Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Villejuif, France., Baldini C; Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Villejuif, France., Postel-Vinay S; Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.; INSERM U981, Gustave Roussy, Villejuif, France., Micol JB; Département d'Hématologie, Gustave Roussy, Villejuif, France., Massard C; Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.; Université Paris-Saclay, Villejuif, France., De Botton S; Département d'Hématologie, Gustave Roussy, Villejuif, France.; Université Paris-Saclay, Villejuif, France.; INSERM U1170, Gustave Roussy, Villejuif, France., Ribrag V; Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.; Département d'Hématologie, Gustave Roussy, Villejuif, France.; INSERM U1170, Gustave Roussy, Villejuif, France., Michot JM; Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.; Département d'Hématologie, Gustave Roussy, Villejuif, France.; INSERM U1170, Gustave Roussy, Villejuif, France.
Publikováno v:
European journal of haematology [Eur J Haematol] 2024 Sep 21. Date of Electronic Publication: 2024 Sep 21.
Autor:
DiNardo CD; Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX., Roboz GJ; Clinical and Translational Leukemia Programs, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Watts JM; Division of Hematology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL., Madanat YF; Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX., Prince GT; Division of Hematologic Malignancy, Johns Hopkins Hospital, Baltimore, MD., Baratam P; Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC., de Botton S; Hematologie Clinique, Institut Gustave Roussy, Villejuif, Faculté Paris-Saclay, Institut Gustave Roussy, Villejuif, France., Stein A; Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Foran JM; Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL., Arellano ML; Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA., Sallman DA; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL., Hossain M; Servier Pharmaceuticals, LLC, Boston, MA., Marchione DM; Servier Pharmaceuticals, LLC, Boston, MA., Bai X; Servier Pharmaceuticals, LLC, Boston, MA., Patel PA; Servier Pharmaceuticals, LLC, Boston, MA., Kapsalis SM; Servier Pharmaceuticals, LLC, Boston, MA., Garcia-Manero G; Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX., Fathi AT; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Publikováno v:
Blood advances [Blood Adv] 2024 Aug 13; Vol. 8 (15), pp. 4209-4220.
Autor:
Annereau, M., Willekens, C., El Halabi, L., Chahine, C., Saada, V., Auger, N., Danu, A., Bermudez, E., Lazarovici, J., Ghez, D., Leary, A., Pistilli, B., Lemare, F., Solary, E., de Botton, S., Desmaris, R.-P., Micol, J.-B.
Publikováno v:
In Leukemia Research April 2017 55:58-64
Autor:
Montesinos P; Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia, Spain., Fathi AT; Leukemia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA., de Botton S; Department of Hematology, Institut Gustave Roussy, Villejuif, France., Stein EM; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY., Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale University and Yale Cancer Center, New Haven, CT., Zhu Y; Bristol Myers Squibb, Philadelphia, PA., Prebet T; Bristol Myers Squibb, Summit, NJ., Vigil CE; Bristol Myers Squibb, Summit, NJ., Bluemmert I; Bristol Myers Squibb, Boudry, Switzerland., Yu X; Bristol Myers Squibb, Summit, NJ., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Publikováno v:
Blood advances [Blood Adv] 2024 May 28; Vol. 8 (10), pp. 2509-2519.
Autor:
Risueño A; Bristol Myers Squibb, Lawrenceville, 3401 Princeton Pike, Lawrence Township, NJ 08648, United States., See WL; Bristol Myers Squibb, Summit, 86 Morris Avenue, Summit, NJ 07901, United States., Bluemmert I; Celgene International Sàrl, a Bristol-Myers Squibb Company, Route de Perreux 1, Boudry 2017, Switzerland., de Botton S; Institut Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif 94805, France., DiNardo CD; The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States., Fathi AT; Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, United States., Schuh AC; Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON M5G 2C4, Canada., Montesinos P; Hospital Universitario y Politécnico La Fe, Avinguda de Fernando Abril Martorell, 106, Valencia 46026, Spain., Vyas P; MRC Molecular Haematology Unit and Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals, Headley Way, Headington, Oxford OX3 9DS, United Kingdom., Prebet T; Bristol Myers Squibb, Summit, 86 Morris Avenue, Summit, NJ 07901, United States., Gandhi A; Bristol Myers Squibb, Summit, 86 Morris Avenue, Summit, NJ 07901, United States., Hasan M; Bristol Myers Squibb, Summit, 86 Morris Avenue, Summit, NJ 07901, United States. Electronic address: maroof.hasan@bms.com.
Publikováno v:
Leukemia research [Leuk Res] 2024 May; Vol. 140, pp. 107497. Date of Electronic Publication: 2024 Mar 27.
Publikováno v:
Journal of Blood Medicine, Vol Volume 7, Pp 171-180 (2016)
Johanna Mondesir1,2 Christophe Willekens3–5 Mehdi Touat6,7 Stéphane de Botton3–5 1Service d’Immunopathologie Clinique, Hôpital Saint Louis, 2CNRS UMR8104, INSERM U1016, Institut Cochin, Université Paris Descartes, Paris, 3Gustave Roussy, Uni
Externí odkaz:
https://doaj.org/article/89d7d87d9bf64724bb600197cf26475c
Autor:
Stein EM; Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Botton S; Institut Gustave Roussy, Paris, France., Cluzeau T; Côte d'Azur University, CHU de Nice Hôpital, Nice, France., Pigneux A; Hematology Clinic, Bordeaux University Hospital, Bordeaux University, Bordeaux, France., Liesveld JL; University of Rochester Medical Center, Rochester, NY, USA., Cook RJ; Division of Hematology/Medical Oncology, Oregon Health and Science University, Portland, OR., Rousselot P; Centre Hospitalier de Versailles, Université Paris-Saclay, Versailles, France., Rizzieri DA; Novant Health Cancer Institute, Winston-Salem, NC, USA., Braun T; Centre Hospitalier Universitiaire Hôpital Avicenne, Bobigny, France., Roboz GJ; Weill Cornell Medicine and the New York Presbyterian Hospital, New York, NY, USA., Lebon D; CHU Amiens, Amiens, France., Heiblig M; Centre Hospitalier Lyon Sud, Pierre-Bénite, France., Baker K; Syros Pharmaceuticals, Cambridge, MA, USA., Volkert A; Syros Pharmaceuticals, Cambridge, MA, USA., Paul S; Syros Pharmaceuticals, Cambridge, MA, USA., Rajagopal N; Syros Pharmaceuticals, Cambridge, MA, USA., Roth DA; Syros Pharmaceuticals, Cambridge, MA, USA., Kelly M; Syros Pharmaceuticals, Cambridge, MA, USA., Peterlin P; Centre Hospitalier Universitaire Nantes, Nantes, France.
Publikováno v:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Dec; Vol. 64 (12), pp. 1992-2001. Date of Electronic Publication: 2023 Aug 12.
Autor:
DiNardo, CD, de Botton, S, Risueño, A, Schuh, AC, Löwenberg, B, Kim, HJ, Vyas, P, Wei, AH, Stein, EM, Döhner, H, Fathi, AT, Martin-Regueira, P, Taningco, L, Bluemmert, I, Yu, X, See, WL, Hasan, M
Publikováno v:
Clinical Lymphoma, Myeloma and Leukemia, 22, S249-S250. Cancer Media Group
Context : IDH2 mutations (mIDH2) occur in ~8%-19% of patients with AML, typically as R140Q (~75%) or R172K (~25%) point mutations, which have distinct functional effects and prognostic relevance. In the phase 3 IDHENTIFY trial, enasidenib did not sig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5183316e221f63004b35c95a9e4c6cdb
https://ora.ox.ac.uk/objects/uuid:ad598452-c6c2-4a77-a80c-48012bd4f2c7
https://ora.ox.ac.uk/objects/uuid:ad598452-c6c2-4a77-a80c-48012bd4f2c7
Autor:
Micol, J.-B., Chahine, C., Woerther, P.-L., Ghez, D., Netzer, F., Dufour, C., Merad, M., Blot, F., Chachaty, E., de Botton, S., Gachot, B.
Publikováno v:
In Clinical Microbiology and Infection July 2014 20(7):O453-O455
Autor:
Desplanques, P.-Y., Burlacu, R., Poinsignon, V., Boussion, H., Borget, I., Wyplosz, B., de Botton, S., Billaud, E., Chachaty, E., Gachot, B., Netzer, F., Micol, J.-B.
Publikováno v:
In Médecine et Maladies Infectieuses April 2014 44(4):174-179